Alzheimer disease (AD) is characterized by progressive cognitive decline in older
individuals accompanied by the presence of two pathological protein aggregates—amyloid …

Over the last five decades, a large body of evidence has accrued for structural and metabolic
brain alterations in schizophrenia. Here we provide an overview of these findings, focusing …

The complement system is an ancient collection of proteolytic cascades with well-described
roles in regulation of innate and adaptive immunity. With the convergence of a revolution in …

Synapse dysfunction and loss are hallmarks of neurodegenerative diseases that correlate
with cognitive decline. However, the mechanisms and therapeutic strategies to prevent or …

Selective serotonin reuptake inhibitors (SSRIs) are widely used for treating neuropsychiatric
disorders. However, the exact mechanism of action and why effects can take several weeks …

Synapse loss has been considered as a major pathological change in Alzheimer's disease
(AD). It remains unclear about whether and how synapse loss relates to functional and …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the
accumulation of beta-amyloid (Aβ) protein and neurofibrillary tangles in the brain, resulting …

In recent years, the field of neuroimaging dramatically moved forward by means of the
expeditious development of specific radioligands of novel targets. Among these targets, the …

Recent studies have demonstrated that neuroplasticity, such as synaptic plasticity and
neurogenesis, exists throughout the normal lifespan but declines with age and is …

Background RNA editing at the Q/R site of GluA2 occurs with~ 99% efficiency in the healthy
brain, so that the majority of AMPARs contain GluA2 (R) instead of the exonically encoded …